Kilambi News
Tuesday, November 17, 2026

Life sciences also notable: Benitec, Prime, Yarrow, ADARx

Life Sciences Sunday, November 15, 2026 - Updated Nov 15, 2026 07:06

Benitec reported a 100 percent responder rate for BB-301, Prime Medicine closed a 143.7 million dollar offering, Yarrow raised 172.5 million dollars, and three FDA goal dates passed on Saturday with no decision published.

Why it matters: Small cap programme and financing updates, plus three pending FDA decisions, set the watch list for the coming week.

Data as of Company releases filed with the SEC on November 12 and 13, 2026, read from the filings; FDA goal date status as reported by PDUFA.bio at November 14, 2026, 7:42 PM Eastern. Yarrow figures from its November 12, 2026 release filed with the SEC, accession 0001566044-26-000017.

Benitec Biopharma reported interim results for BB-301, its gene therapy for swallowing difficulty in oculopharyngeal muscular dystrophy, showing a 100 percent responder rate across the low dose and high dose cohorts presented at the European Society of Gene and Cell Therapy congress. The company, which held about 176 million dollars in cash at September 30, expects to finalise the pivotal study design in the first quarter of 2027 and to start that trial in mid 2027.

Prime Medicine closed an underwritten offering, including full exercise of the underwriters option, raising 143.7 million dollars in gross proceeds, leaving pro forma cash of about 209.5 million dollars and a runway through 2027. The company dosed the first patient in its Phase 1/2 trial of PM577a in Wilson disease, received FDA clearance of its investigational new drug application for PM647 in alpha-1 antitrypsin deficiency, and plans a biologics licence application for PM359 in the first half of 2027, with initial clinical data from the liver programmes expected in 2027.

Yarrow Bioscience completed an underwritten public offering of about 172.5 million dollars and held 268.9 million dollars in cash at September 30, which it expects to fund operations into 2030. Enrolment continues in the Phase 2a portion of its DIRECTION-GD trial of YB-101, an anti TSHR antibody, in Graves disease, with topline results expected in the second half of 2027.

ADARx Pharmaceuticals reported that its initial public offering and concurrent private placement raised about 602.5 million dollars in gross proceeds, funding three Phase 2 trials of agazisiran in complement mediated diseases. The FDA granted Fast Track designation in August 2026 to its onvuzosiran programme, for prevention of hereditary angioedema attacks.

Three FDA goal dates fell on Saturday, November 14, and no decision on any of them had been published as of Saturday evening: Summit Therapeutics ivonescimab with chemotherapy in EGFR mutated lung cancer, Cytokinetics aficamten label update from the MAPLE-HCM study in obstructive hypertrophic cardiomyopathy, and Teva IGALMI sublingual film. A goal date is the agency target, not a promise of a decision that day, and all three remain pending watches for the coming week.

Sources

  1. Benitec Biopharma releases first quarter 2027 fiscal year financial results and provides operational update - Benitec Biopharma, via SEC filing - 2026-11-13
  2. Prime Medicine reports third quarter 2026 financial results and provides business updates - Prime Medicine, via SEC filing - 2026-11-12
  3. ADARx reports third quarter 2026 financial results and provides business updates - ADARx Pharmaceuticals, via SEC filing - 2026-11-12
  4. FDA approval decisions this week, November 9 to 15, 2026 - PDUFA.bio - 2026-11-14